This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Learn about the efficacy and safety of Somavert, its tumour impact and its effect on co-morbidity management through clinical and real world data

The acromegaly disease activity tool designed to help monitor your patients

Advice and support services to help you and your patients optimise your experience with Somavert about the efficacy and safety of Somavert through clinical and real world data

Learn about funding and reimbursement England, Scotland, Wales and Northern Ireland

Watch and listen to acromegaly experts talk about various topics in the disease area as well as recordings from our National Nurse Meeting and the Acromegaly co-morbidity series

Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Somavert is used in the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-I concentrations or was not tolerated.

Personalised dosing

Somavert has a positive dose response, allowing flexible dose titration to achieve IGF-I normalisation and improve symptoms1,2

IGF-I normalisation rates with increasing dose strengths

Percentage of Somavert patients achieving IGF-I normalisation after 12 weeks of treatment2

Somavert is a daily subcutaneous injection available in five vial sizes of 10 mg,         15 mg, 20 mg, 25 mg and 30 mg

A loading dose of 80mg Somavert should be administered subcutaneously under medical supervision.  Following this, 10mg Somavert should be administered once daily as a sub-cutaneous injection.  
​​​​​​​Dose adjustments should be based on serum IGF-I levels. Serum IGF-I concentrations should be measured every four to six weeks and appropriate dose adjustments made in increments of 5 mg/day in order to maintain the serum IGF-I concentration within the age-adjusted normal range and to maintain an optimal therapeutic response.1
The dose range of Somavert is 10-30mg daily.  The maximum dose should not exceed 30mg/day.1

  • Any daily dose can be self-administered with a single injection1
  • No need for patients to visit a clinic after their loading dose is administered in hospital
  • No time or food restrictions
  • Pre-filled diluent syringe with enlarged finger grip and plunger for convenience
  • Store the powder vials in a refrigerator (2°C – 8°C). However, they may be stored at room temperature up to a maximum of 25°C for a single period of up to 30 days.†
  • Diluent syringe can be kept out of the fridge (<30°C) prior to reconstitution. Do not freeze†​​​​​​​

†Please refer to the Summary of Product Characteristics for the full information regarding storage

​

Homecare services 

We offer a range of services that help your patients at home with medication delivery and face-to-face support 

Learn more

The Somavert prescribing guide

Find information on funding, homecare and follow-up

Download the guide

Somavert efficacy

Discover IGF-I normalisation rates with Somavert

Learn more

Explore more

Contact us

To find out more about Somavert dosing, supporting your patients or to order starter kits

Contact us

** This is an optional area where footnotes can live.

Monitoring patients with ACRODAT

Track IGF-I, symptoms and co-morbidities to help monitor and optimise support for your acromegaly patients at every stage of their journey

Learn more

** This is an optional area where footnotes can live.

References
​​​​​​​
1. Somavert Summary of Product Characteristics.  Great Britain available here. Northern Ireland available here
2. Trainer PJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342(16):1171–7.

PP-SOM-GBR-1122. January 2022

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?